Immediate Impact
2 from Science/Nature 56 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients
2024 Standout
Works of Carlos E. Vigil being referenced
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
2015
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Carlos E. Vigil | 323 | 248 | 141 | 249 | 46 | 748 | |
| Lurdes Zamora | 309 | 265 | 240 | 266 | 54 | 792 | |
| G. Ucci | 459 | 353 | 199 | 353 | 61 | 921 | |
| Mahesh Seetharam | 254 | 268 | 123 | 393 | 61 | 885 | |
| Nanao Kamada | 267 | 344 | 94 | 181 | 27 | 767 | |
| Michael Neat | 326 | 267 | 151 | 252 | 35 | 835 | |
| John Dervenoulas | 341 | 293 | 201 | 210 | 56 | 923 | |
| Gabriella Sammarelli | 461 | 396 | 192 | 431 | 38 | 925 | |
| Paule‐Marie Carli | 367 | 215 | 218 | 266 | 29 | 798 | |
| Afua A. Mensah | 303 | 626 | 140 | 171 | 29 | 908 | |
| Mona Anand | 267 | 251 | 267 | 209 | 43 | 896 |
All Works
Login with ORCID to disown or claim papers
Loading papers...